Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: puborectalis who wrote (3077)	5/30/1998 9:59:00 PM
From: Solid	Respond to of 9523

Stephen & Anthony- I appreciate both of your posts and the information they contain. Any comment on my post # 3068 to Bigk? I agree with your assessments of both PFE and where they should be vs. currently are with share price. L/T I have no ?'s, but s/t am curious what your read on the market and pfe may be, I still hold a good number of June options. Thanks for any insights which I might add to my own! Solid

To: puborectalis who wrote (3077)	6/1/1998 6:52:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Pfizer's Viagra Total Sales Drop for 2nd Week; Refills Increase Bloomberg News June 1, 1998, 5:45 p.m. ET Pfizer's Viagra Total Sales Drop for 2nd Week; Refills Increase New York, June 1 (Bloomberg) -- Pfizer Inc.'s Viagra had 5.1 percent fewer prescriptions filled in the week ended May 22, marking the second weekly drop in total sales of the first pill to treat impotence. Total Viagra prescriptions fell to 282,597 from 297,666 in the week ended May 15, said IMS Health, an industry consulting group. In the week ended May 8, Viagra had 303,424 prescriptions. The slowing of Viagra's once-spectacular growth is not a concern because refills rose 31 percent to 45,972 in the May 22 week, analysts said. Viagra became one of the best-selling U.S. drugs within weeks of its April introduction. Prescriptions likely will have slipped again for the week ended May 29 because of the Memorial Day holiday and concerns about a report of the deaths of six Viagra users. Pfizer last week said these deaths were the results of improper use of Viagra or heart attack and stroke. ''Maybe it was like a cold shower,'' said Stephen O'Neil, an analyst with Hilliard Lyons, who has a ''hold'' rating on Pfizer. ''People would stop and think about (using Viagra).'' Pfizer fell 15/16 to 103 7/8. Enthusiasm about early Viagra sales pushed it to a record high of 121 3/4 on April 21. In the past year, Pfizer has doubled on prospects for Viagra. The pill has expanded the market for impotence sales, once dominated by less convenient methods. The U.S. Food and Drug Administration said today a review of medical records shows only four of the six men who reportedly died after using Viagra had definitely taken the drug. Two other reports proved to be unreliable or circumstantial. Warning Label Pfizer last week said three of the people in the report died because of taking Viagra with common heart medicine, such as nitroglycerin. Viagra's warning label already warned users not to take the drug if they are taking this class of drugs, called nitrates, used to treat severe chest pain known as angina. Three other deaths seemed to stem from heart attacks and stroke. Sexual intercourse is often a cause of these events in older men. Even if the next report from IMS shows a slip in total sales, Viagra sales are likely to recover in time, analysts said. ''I don't view (this week's IMS report) as being close to disappointing for Pfizer,'' said Carl Seiden, an analyst with J.P. Morgan Securities Inc., who has a ''buy'' rating on Pfizer. IMS Health is a unit of Westport, Connecticut-based Cognizant Corp. --Kerry Dooley in the Princeton newsroom (609) 279-4016/dd